Patient, disease, and treatment characteristics associated with risk of progression to MPN-AP/MPN-BP
| Patient factor |
| Advanced patient age (>60 vs >70 years)57,58 |
| Disease factors |
| Longer disease duration31 |
| Higher risk for patients with PMF compared to ET and PV11 |
| Platelet count <150 × 109/L, leukocytosis, transfusion dependence, peripheral blasts ≥3%16,58,59 |
| Splenomegaly of ≥20 cm from left costal margin or requirement for splenectomy59 |
| Bone marrow reticulin fibrosis57 |
| Abnormal karyotype58,59 |
| Lower risk with CALR mutations60 |
| High-risk mutations (eg, TP53, ASXL1, SRSF2, IDH2, EZH2)4,60 |
| Higher DIPSS, MYSEC-PM, or MIPSS70v2.0 score16 |
| Treatment factors |
| Prior treatment with alkylating agents and pipobroman20,58 |
| Lower risk in patients treated with IFN16 |
| Patient factor |
| Advanced patient age (>60 vs >70 years)57,58 |
| Disease factors |
| Longer disease duration31 |
| Higher risk for patients with PMF compared to ET and PV11 |
| Platelet count <150 × 109/L, leukocytosis, transfusion dependence, peripheral blasts ≥3%16,58,59 |
| Splenomegaly of ≥20 cm from left costal margin or requirement for splenectomy59 |
| Bone marrow reticulin fibrosis57 |
| Abnormal karyotype58,59 |
| Lower risk with CALR mutations60 |
| High-risk mutations (eg, TP53, ASXL1, SRSF2, IDH2, EZH2)4,60 |
| Higher DIPSS, MYSEC-PM, or MIPSS70v2.0 score16 |
| Treatment factors |
| Prior treatment with alkylating agents and pipobroman20,58 |
| Lower risk in patients treated with IFN16 |
DIPSS, Dynamic International Prognostic Scoring System; MYSEC-PM, myelofibrosis secondary to PV and ET Collaboration Prognostic Model.